Covid19 vax jab linked to blood clots 43669 VAERS reports of blood clotting disorders Oct. 21, 2022 Part 8, FDA took year+ to follow up on increase in serious adverse events in elderly people
Covid19 vax jab linked to blood clots 43669 VAERS reports of blood clotting disorders Oct. 21, 2022 Part 8, FDA took year+ to follow up on increase in serious adverse events in elderly people
“VAERS data from Dec. 14, 2020, to Oct. 21, 2022, for all age groups combined, show:
43,699 reports of blood-clotting disorders. Of those, 29,940 reports were attributed to Pfizer, 9,849 reports to Moderna and 3,820 reports to J&J.
CDC pressured FDA to authorize COVID boosters without clinical trials
The CDC pressured U.S. regulators to clear COVID-19 boosters without clinical trial data, according to emails obtained by Judicial Watch.
CDC officials relayed to counterparts at the FDA in early August 2021 that they wanted authorization for Moderna and Pfizer boosters, as data began showing that the vaccines weren’t working as well as initially promoted.
The conversation took place on a call that was described by Dr. Phil Krause, a top FDA official, to several other FDA workers. On that call, the CDC “evidently stated” they would assemble all the data they were aware of on third dosing in the immunocompromised setting and send it to the FDA in hopes they would authorize a third dose for those with compromised immune systems under Emergency Use Authorization.
All COVID-19 vaccines were authorized only for emergency use at that time. No boosters had been authorized and no clinical data were available for a third vaccine dose. Less than two weeks later, the FDA authorized boosters for certain people, including immunocompromised persons.
The agency said “a thorough review of the available data” concluded the group “may benefit” from a third dose. The only data cited on efficacy were from two studies, one conducted by French researchers and another by Canadian researchers. Pfizer and Moderna hadn’t completed any clinical trials.
FDA slow-walked studies on COVID vaccine safety signals in elderly
The FDA took more than a year to follow up on a potential increase in serious adverse events in elderly people who received Pfizer’s COVID-19 vaccine, according to an investigative report published Tuesday by The BMJ.
According to The BMJ, in July 2021, the FDA “quietly disclosed” the findings of a potential increase in four types of serious adverse events in elderly people who had received a Pfizer COVID-19 vaccine: acute myocardial infarction, disseminated intravascular coagulation, immune thrombocytopenia, and pulmonary embolism.”
